|
Oxford Nanopore Technologies PLC on Wednesday announced a collaboration aimed at advancing automated sequencing-based solutions. The Oxford-based specialist in DNA and RNA sequencing technologies said it is teaming up with Sunnyvale, California-based Cepheid, a molecular diagnostics subsidiary of Washington DC-based life sciences and diagnostics company Danaher Corp. The partnership is a strategic collaboration aimed at developing and commercialising a ‘seamless’ end-to-end workflow to advance in the field of sequencing for infectious diseases. Oxford Nanopore said: ‘The two companies have completed a successful proof-of-concept study which demonstrated the feasibility of using Cepheid’s cartridge-based GeneXpert system for sample and library preparation in a workflow with Oxford Nanopore’s molecular analysis platform.’ The companies aim to launch a joint research use only workflow that will enable customers to leverage rapid information-rich sequencing in-house for infectious disease analysts, returning results within hours instead of days. Oxford Nanopore Chief Executive Officer Gordon Sanghera said: ‘This collaboration represents an important step forward in delivering new and improved workflow options to better understand infectious diseases. By partnering to integrate our richer data, rapid insights, and accessible and affordable sequencing technology with Cepheid’s GeneXpert architecture, we are establishing a workflow foundation that is positioned for future expansion into scaled routine clinical use.’ Oxford Nanopore shares fell 6.2% to 100.60 pence each on Wednesday afternoon in London, while Danaher shares were 2.0% lower in pre-market trading at $171.08 each in New York. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
